Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fast large scale full-wave multiple-scattering computation for three-dimensional random rough surfaces.

Scientific reports·2026
Same author

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Cell reports. Medicine·2026
Same author

How I Do It: "And That's a BINGO!" Using a Self-Directed, Gamified Instrument to Structure Learning on the Obstetrics Clerkship.

Journal of surgical education·2026
Same author

[<sup>68</sup>Ga]Ga-DOTA-5G PET/CT Detects Brain and Bone Metastases in a Patient with Metastatic Pancreatic Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

<sup>90</sup>Y Radiation Segmentectomy for Curative Intent in HCC: From Art to Science.

Radiology·2026
Same author

Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma.

Radiology·2026

Related Experiment Video

Updated: Jul 2, 2025

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K

Radiation Segmentectomy for Hepatocellular Carcinoma.

Muhamad Serhal1, Farnaz Dadrass2, Edward Kim2

  • 1Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Current Oncology (Toronto, Ont.)
|February 23, 2024
PubMed
Summary

Radiation segmentectomy (RADSEG) offers a new approach for earlier-stage hepatocellular carcinoma (HCC), evolving from trans-arterial radioembolization (TARE). This review explores RADSEG

Keywords:
Barcelona Clinic Liver Cancer paradigmhepatocellular carcinomaradiation segmentectomyradioembolization

More Related Videos

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
04:41

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy

Published on: March 10, 2023

1.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

431

Related Experiment Videos

Last Updated: Jul 2, 2025

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K
Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
04:41

Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy

Published on: March 10, 2023

1.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

431

Area of Science:

  • Hepatobiliary oncology
  • Interventional radiology
  • Radiation oncology

Background:

  • Trans-arterial radioembolization (TARE) with Yttrium-90 is established for advanced hepatocellular carcinoma (HCC).
  • Radiation segmentectomy (RADSEG) represents an evolution, delivering targeted ablative radiation doses to specific liver segments.
  • RADSEG is emerging as a viable treatment for earlier-stage HCC.

Purpose of the Study:

  • To provide an in-depth review of Radiation Segmentectomy (RADSEG) for hepatocellular carcinoma (HCC).
  • To explore RADSEG's technical aspects, dosimetry, and patient selection criteria.
  • To assess RADSEG's safety, efficacy, and integration into the Barcelona Clinic Liver Cancer (BCLC) treatment paradigm.

Main Methods:

  • Review of current literature on RADSEG for HCC.
  • Analysis of technical considerations and dosimetry advancements in RADSEG.
  • Comparative evaluation of RADSEG outcomes against traditional HCC treatments (TACE, ablation, resection).

Main Results:

  • RADSEG demonstrates potential as an effective treatment for earlier-stage HCC.
  • Technical and dosimetry advancements are refining RADSEG delivery.
  • RADSEG outcomes are comparable to established locoregional therapies.

Conclusions:

  • RADSEG is an evolving, potentially curative treatment for select HCC patients.
  • Integration into the BCLC staging system is crucial for optimal patient selection.
  • Further research is needed to define RADSEG's long-term role and compare it with other HCC therapies.